FindTrial
Sign In

Cancelled by the investigator Randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild/common novel coronavirus pneumonia (COVID-19)

Randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild/common novel coronavirus pneumonia (COVID-19)

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030082
Enrollment
Unknown
Registered
2020-02-22
Start date
2020-02-23
Completion date
Unknown
Last updated
2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus pneumonia (COVID-19)

Interventions

experimental group:dihydroartemisinin piperaquine tablets combined with antiviral treatment.
control group:antiviral treatment was selected as: a-interferon and Ardibdol

Sponsors

The First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with mild/common novel coronavirus pneumonia who agreed to participate in this trial and signed the informed consent form

Exclusion criteria

Exclusion criteria: The investigator considers that the subject has other conditions that make him/her unsuitable to participate in the clinical trial or other special circumstances.

Design outcomes

Primary

MeasureTime frame
The time when the nucleic acid of the novel coronavirus turns negative;Conversion to heavy/critical type;—

Secondary

MeasureTime frame
T cell recovery time;Remission time of fever;Improvement of chest imaging;eukocyte and lymphocyte recovery time;Frequency of serious adverse drug reactions;—

Countries

China

Contacts

Public ContactHong tao

The First Affiliated Hospital of Nanchang University

ht2000@vip.sina.com+86 13803535961

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026